- Diabetes, obesity and metabolism
- Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
-
A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Deep Dutta, Shahjada Selim
-
Endocrinol Metab. 2024;39(1):109-126. Published online January 23, 2024
-
DOI: https://doi.org/10.3803/EnM.2023.1839
-
-
2,316
View
-
85
Download
-
3
Web of Science
-
6
Crossref
-
 Abstract
 PDF Supplementary Material PubReader  ePub
- Background
No recent meta-analysis has holistically analyzed and summarized the efficacy and safety of omarigliptin in type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to address this knowledge gap.
Methods
Electronic databases were searched to identify randomized controlled trials (RCTs) that included patients with T2DM who received omarigliptin in the intervention arm. The control arm consisted of either a placebo (passive control group [PCG]) or an active comparator (active control group [ACG]). The primary outcome assessed was changes in hemoglobin A1c (HbA1c), while secondary outcomes included variations in glucose levels, achievement of glycemic targets, adverse events (AEs), and hypoglycemic events.
Results
From 332 initially screened articles, data from 16 RCTs involving 8,804 subjects were analyzed. Omarigliptin demonstrated superiority over placebo in reducing HbA1c levels (mean difference, –0.58%; 95% confidence interval, –0.75 to –0.40; P<0.00001; I2=91%). Additionally, omarigliptin outperformed placebo in lowering fasting plasma glucose, 2-hour postprandial glucose, and in the percentage of participants achieving HbA1c levels below 7.0% and 6.5%. The glycemic efficacy of omarigliptin was similar to that of the ACG across all measures. Although the omarigliptin group experienced a higher incidence of hypoglycemic events compared to the PCG, the overall AEs, serious AEs, hypoglycemia, and severe hypoglycemia were comparable between the omarigliptin and control groups (PCG and ACG).
Conclusion
Omarigliptin has a favorable glycemic efficacy and safety profile for managing T2DM.
-
Citations
Citations to this article as recorded by  - Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis
A.B.M. Kamrul-Hasan, Mohammad Abdul Hannan, Muhammad Shah Alam, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra, Shahjada Selim, Deep Dutta
Medicine.2024; 103(25): e38592. CrossRef - Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathy
Ashraf Al Madhoun
World Journal of Diabetes.2024; 15(8): 1654. CrossRef - Inhibition of Oxidative Stress and Related Signaling Pathways in Neuroprotection
Maja Jazvinšćak Jembrek
Antioxidants.2024; 13(9): 1033. CrossRef - Safety and Efficacy of the Novel RNA Interference Therapies for Hypertriglyceridemia and Mixed Hyperlipidemia Management: A Systematic Review and Meta-analysis
A.B.M. Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Sunetra Mondal, Saptarshi Bhattacharya, Sanjay Kalra
Endocrine Practice.2024;[Epub] CrossRef - Hepatobiliary effects and safety of tirzepatide: A systematic review and meta‐analysis
A. B. M. Kamrul‐Hasan, Deep Dutta, Lakshmi Nagendra, Mohammad Shafi Kuchay, Md. Saiful Islam, Joseph M. Pappachan
Diabetes, Obesity and Metabolism.2024;[Epub] CrossRef - Efficacy and Safety of Ertugliflozin Compared to Placebo in Patients With Type 2 Diabetes: An Updated Systematic Review and Meta‐Analysis
A. B. M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Mohammad Abdul Hannan, Deep Dutta, Lakshmi Nagendra, Shahjada Selim, Eusebio Chiefari
Journal of Diabetes Research.2024;[Epub] CrossRef
|
KES
